What is ClearFlow?
ClearFlow specializes in the development and commercialization of high-impact medical technologies, most notably its PleuraFlow Active Clearance Technology and ClearFix Rigid Sternal Fixation systems. These products are engineered to address the persistent challenge of Retained Blood Syndrome, a common complication that can lead to increased hospital stays and higher healthcare costs. By focusing on the intersection of surgical efficiency and patient recovery, ClearFlow provides healthcare institutions with the tools necessary to optimize resource utilization. The company maintains a strong commitment to clinical excellence, supporting medical professionals through comprehensive education and technical support, thereby ensuring the seamless integration of their proprietary technologies into standard cardiac care protocols.
How much funding has ClearFlow raised?
ClearFlow has raised a total of $21.8M across 8 funding rounds:
Private Equity
$1.2M
Private Equity
$4.9M
Private Equity
$4.2M
Debt
$2.8M
Private Equity
$5.5M
Debt
$350K
Debt
$2.1M
Private Equity (2010): $1.2M, investors not publicly disclosed
Private Equity (2011): $4.9M, investors not publicly disclosed
Private Equity (2013): $4.2M, investors not publicly disclosed
Debt (2014): $2.8M, investors not publicly disclosed
Private Equity (2015): $5.5M, investors not publicly disclosed
Debt (2020): $350K led by PPP
Debt (2025): $2.1M, investors not publicly disclosed
Key Investors in ClearFlow
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for ClearFlow?
With the successful closure of this major enterprise-level funding, ClearFlow is well-positioned to accelerate its market penetration and expand its research and development pipeline. The strategic allocation of these funds will likely focus on scaling the distribution of its flagship clearance and fixation technologies to a broader network of global healthcare providers. Furthermore, the company is expected to leverage this financial backing to enhance its clinical evidence base, potentially exploring new indications for its existing product suite. As ClearFlow navigates its current growth phase, the focus remains on driving long-term value for stakeholders while maintaining its core mission of advancing surgical practices and improving the standard of care in cardiac medicine.
See full ClearFlow company page
